Viewing Study NCT02853318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:52 AM
Ignite Modification Date: 2026-03-01 @ 12:34 PM
Study NCT ID: NCT02853318
Status: COMPLETED
Last Update Posted: 2021-10-06
First Post: 2016-07-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: Roswell Park Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tube Clear Cell Adenocarcinoma View
None Fallopian Tube Endometrioid Adenocarcinoma View
None Fallopian Tube Mucinous Adenocarcinoma View
None Fallopian Tube Serous Adenocarcinoma View
None Ovarian Clear Cell Adenocarcinoma View
None Ovarian Endometrioid Adenocarcinoma View
None Ovarian Mucinous Adenocarcinoma View
None Ovarian Serous Adenocarcinoma View
None Primary Peritoneal Serous Adenocarcinoma View
None Recurrent Fallopian Tube Carcinoma View
None Recurrent Ovarian Carcinoma View
None Recurrent Primary Peritoneal Carcinoma View
None Undifferentiated Fallopian Tube Carcinoma View
None Undifferentiated Ovarian Carcinoma View
Keywords: